Patents by Inventor Barnali Paul

Barnali Paul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Purine based compounds as toll-like receptor 9 antagonist
    Patent number: 11168084
    Abstract: The present invention provides novel purine based compounds of formula 1, method of preparation of purine based compounds and its composition useful for inhibiting signalling through Toll-like receptors. These compounds are useful in inhibiting immune stimulation involving toll-like receptor 9 (TLR9). These can be used in treatment of autoimmune disease and inflammation where aberrant activation of TLR9 plays role.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: November 9, 2021
    Assignee: Council of Scientific & Industrial Research
    Inventors: Arindam Talukdar, Dipyaman Ganguly, Ayan Mukherjee, Barnali Paul, Oindrila Rahaman, Biswajit Kundu, Swarnali Roy, Raychaudhuri Deblina
  • PURINE BASED COMPOUNDS AS TOLL-LIKE RECEPTOR 9 ANTAGONIST
    Publication number: 20200347062
    Abstract: The present invention provides novel purine based compounds of formula 1, method of preparation of purine based compounds and its composition useful for inhibiting signalling through Toll-like receptors. These compounds are useful in inhibiting immune stimulation involving toll-like receptor 9 (TLR9).
    Type: Application
    Filed: November 5, 2018
    Publication date: November 5, 2020
    Inventors: Arindam TALUKDAR, Dipyaman GANGULY, Ayan MUKHERJEE, Barnali PAUL, Oindrila RAHAMAN, Biswajit KUNDU, Swarnali ROY, Raychaudhuri DEBLINA
  • Blocking toll-like receptor 9 signaling with small molecule antagonist
    Patent number: 10662177
    Abstract: The present invention relates to small molecule 4-(piperazin-1-yl)quinazolin-2-amino compounds with formula (I) useful for inhibiting signalling by certain toll-like receptors (TLRs), especially TLR9. Toll-like receptors (TLRs) are members of the larger family of evolutionarily conserved pattern recognition receptors which are critical first line of defense for self-nonself discrimination by the host immune response. Aberrant TLR9 activation is implicated in autoreactive inflammation in different autoimmune diseases. The invention depicts compounds with formula (I), composition and methods can be used in a number of clinical applications, including as pharmaceutical agents and methods for treating conditions involving unwanted immune activity due to TLR9 activation.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: May 26, 2020
    Assignee: Council of Scientific & Industrial Research
    Inventors: Arindam Talukdar, Dipyaman Ganguly, Barnali Paul, Ayan Mukherjee, Shounak Roy, Swarnali Roy, Amrit Raj Ghosh, Roopkatha Bhattacharya, Oindrila Rahaman, Biswajit Kundu
  • BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST
    Publication number: 20190092758
    Abstract: The present invention relates to small molecule4-(piperazin-1-yl)quinazolin-2-amino compounds with formula (I) useful for inhibiting signalling by certain toll-like receptors (TLRs), especially TLR9. Toll-like receptors (TLRs) are members of the larger family of evolutionarily conserved pattern recognition receptors which are critical first line of defence for self-nonself discrimination by the host immune response. Aberrant TLR9 activation is implicated in autoreactive inflammation in different autoimmune diseases. The invention depicts compounds with formula (I), composition and methods can be used in a number of clinical applications, including as pharmaceutical agents and methods for treating conditions involving unwanted immune activity due to TLR9 activation.
    Type: Application
    Filed: March 21, 2017
    Publication date: March 28, 2019
    Inventors: Arindam Talukdar, Dipyaman Ganguly, Barnali Paul, Ayan Mukherjee, Shounak Roy, Swarnali Roy, Amrit Raj Ghosh, Roopkatha Bhattacharya, Oindrila Rahaman, Biswajit Kundu